Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| DYN | UAA | |
|---|---|---|
Market Cap | $2.86B | $2.08B |
Volume | 3,341,579 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $8.14 |
52-Week Low | $14.60 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $2.18B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Under Armour (UAA) trades at $4.79, down 2.84% on the day, amid mixed signals. The stock shows a bullish technical trend but faces fundamental headwinds with a net loss of $201.27M in 2025 and negative profit margins. Recent news highlights the company's focus on product simplification and margin recovery despite revenue weakness, with Q1 2027 earnings beating estimates but revenue falling short.
The outlook is cautious; while cost discipline supports margins, persistent revenue declines and negative cash flow pose risks. Analyst consensus is a 'Hold' with a $5.79 price target, suggesting limited upside. Investors should weigh margin improvements against top-line challenges and high short interest, which could lead to volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
